Reading the tape
LSE: 0JW9.L
Lite Strategy, Inc.
Healthcare · Medical - Pharmaceuticals
Market Cap
$7.59M
52w High
$7.86
52w Low
$1.14
P/E
-0.19
Volume
104.00
Outstanding Shares
6.66M
Price vs Fundamentals
Why The Stock Is Moving
Likely multiple compressionModerate confidence
Note: The most recent financial data is over 3 months old. Metrics shown may not reflect the latest reporting period.
1Y Price: -45.19%FCF (TTM): 72%
What changed
The stock fell 45.19% over the last year. Free cash flow grew 72% over the trailing twelve months.
What the market seems to be pricing
Visible fundamentals weakened far less than the stock price. The market appears to be discounting durability, risk, or trust rather than just the latest reported numbers.
What would invalidate this read
This read is wrong if revenue rolls over, margins compress again, or free cash flow keeps deteriorating. In that case the selloff would be catching up with weaker business quality rather than just a lower multiple.
Company profile
Lite Strategy, Inc. a clinical-stage pharmaceutical company, focuses on the development of various therapies for the treatment of cancer.
CEOJustin J. File
SectorHealthcare
IndustryMedical - Pharmaceuticals
Employees28
IPO dateJan 29, 2018
Valuation
Forward P/E—
EV/EBITDA-0.71
Enterprise value$12.17M
Stock splits
Apr 17, 2023↓ Reverse
Every 20 shares became 1
Profitability & growth
Revenue growth—
Gross margin0%
Operating margin0%
ROE-94.18%▼274.92%vs FY2024
Analyst consensus
RatingHold
Target price—
3
Buy
7
Hold
1
Sell
Analyst ratings tend to be lagging indicators. Use as one signal among many.
Earnings
Full quarter-by-quarter history of actuals vs estimates. Switch into compare mode to inspect one metric year-over-year.
Next report
May 15, 2026
Q2 FY26 · EPS est -$3.12 · Revenue est $5.41M
View